TickerTalks
Browse all tickers →
TickerTalks›$ARDX
ARARDX

Ardelyx, Inc.

$ARDX·$988M·Biotechnology·Healthcare
$3.78-0.8%YTD-14.2%1Y-40.9%
Mentions · last 7 days
2026-08-22: 12 posts2026-08-23: 10 posts96+10%
Price updated 10h ago·X counts updated 8d ago
ARARDX
$ARDXArdelyx, Inc.
$3.78-0.79%96 posts+10%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $ARDX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storySelling offAI verdict · as of 2026-09-01

Falling on heavy selling — points lower unless it turns around.

Ardelyx is trading at 2% of the 52-week range on IBSRELA guide cuts and legal investigations — the drug works, execution doesn't.

Ardelyx is a gastrointestinal-and-kidney biopharm with two commercial products — IBSRELA (IBS with constipation) and XPHOZAH (hyperphosphatemia). The stock is at 2% of the 52-week range on IBSRELA guide cuts, unresolved payer step edits, and now multiple securities-fraud investigations.

  • Revenue growth is real: last four quarters printed 8-33% YoY at operating margin -35% to +4% — the underlying products are growing, but the guide cuts and payer friction are the near-term drag.
  • Analyst FY27 EPS at +$0.48 (from -$0.07 FY26) implies a big swing to profitability — the FY27 revenue estimate of $740M is achievable if IBSRELA prescriptions continue growing at all-time highs.
  • Position sits at only 2.1% of the 52-week range with volume 88% of normal — deep distribution zone, and the coordinated insider selling on Aug 25 (six officers/directors sold ~$412K combined) is unusual and directionally negative.
  • The Aug 17 announcement that Chief Commercial Officer Eric Foster resigned effective Aug 28 to pursue another opportunity is a credibility problem — CCO departures during a commercial launch aren't good.

The path forward requires the Oct 29 Q3 print to show IBSRELA prescription momentum holding, payer step-edit resolution progress, and clarity on Levi & Korsinsky investigations. Another guide cut plus escalation seals the breakdown; a clean CCO replacement plus IBSRELA volume acceleration restarts the case.

Agrees with X sentimentAligned with the split — value buyers pointing to Q2 revenue +31% and IBSRELA prescription demand at all-time highs is real, but the frustrated longs' 17-year CEO Raab, slashed 2026 IBSRELA guide, and unresolved payer step edits are honest management-execution concerns. Both agreeing 'the drug works, management can't monetize it' is the fair honest read.

What to watch: The Oct 29 Q3 print — IBSRELA prescription momentum, payer step-edit resolution progress, and Levi & Korsinsky securities-fraud investigation status. Another guide cut plus escalation of the securities investigations seals the breakdown; a clean CCO replacement plus IBSRELA volume acceleration restarts the case.

On the calendar: 2026-10-29 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment10 posts analyzed · as of 2026-08-31

Sentiment is split. Value buyers point to Q2 revenue up 31% and IBSRELA prescription demand at all-time highs, arguing the roughly $950M market cap prices in permanent damage that isn't actually there. Frustrated longs counter that 17 years under CEO Raab, a slashed 2026 IBSRELA guide, and unresolved payer step edits demand board intervention. Both camps agree the drug works; they disagree on whether management can monetize it.

Read the AI verdict + X sentiment for $ARDX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Commercial biotech with tenapanor approved to block phosphate absorption in dialysis patients with hyperphosphatemia.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ARDX.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $ARDX

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+48.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-23.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-9.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-8.7%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-2.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3.2Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-38.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
91.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.07$-0.07-7.0%
Q1 2026Apr 30, 2026$-0.15$-0.13-15.4%
Q4 2025Feb 19, 2026$0.02$0.020.0%
Q3 2025Oct 30, 2025$-0.00$-0.06+93.3%
Next earningsThu, Oct 29·consensus EPS $-0.03

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$94.5M+27.5%94.9%-34.7%$-0.15$-32.3M
Q4 FY25$125.2M+7.8%90.6%4.1%$-0.00$20.6M
Q3 FY25$110.3M+12.3%95.6%4.2%$-0.00$209K
Q2 FY25$97.7M+33.4%86.7%-14.7%$-0.08$-26.0M

Forward consensus

5-year forecast · up to 8 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$541.5M$532.0M – $548.7M-$0.07-$0.15 – $0.028
FY27$739.6M$698.4M – $771.0M$0.48$0.25 – $0.708
FY28$983.7M$855.1M – $1.1B$1.15$0.72 – $1.518
FY29$1.3B$1.2B – $1.3B$1.81$1.67 – $1.947
FY30$1.4B$1.4B – $1.5B$2.13$1.96 – $2.297

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.2%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-21.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-35.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 237.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.735-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 21Susan HohenleitnerCFO1.6K sh$6KSellAug 21Reilly Joseph JamesSee Remarks4.0K sh$15KSellAug 21John E BishopSee Remarks19.8K sh$76KSellAug 21Brady James ParkerChief Human Resources Officer15.1K sh$58KSellAug 21Foster Eric DuaneChief Commercial Officer8.6K sh$33KSellAug 21Mike KelliherChief Business Officer7.8K sh$30KSellAug 21Laura A WilliamsChief Patient Officer10.7K sh$41KSellAug 21Michael RaabCEO58.6K sh$226KSellJul 15Michael RaabCEO41.7K sh$211KSellJun 18Laura A WilliamsChief Patient Officer81.9K sh$490K
1–10 of 22
+ 13 other (7 awards · 6 exempts) in window

See when $ARDX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDAug 68-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

ARDX filed an 8-K (Item 2.02) reporting its financial results, filed 2026-08-06. The actual financial figures are in the attached press release (Exhibit 99.1), not reproduced in the body excerpt. This is a material disclosure; investors should review the press release for beat/miss details and guidance.

8-KMaterial debt obligationJul 28-K — Item 2.03: Material debt obligation
AI summary

Ardelyx, Inc. (ARDX) drew down $50.0 million under a new Term F Loan tranche on June 29, 2026, under its existing loan and security agreement with SLR Investment Corp. as collateral agent — a facility first established in February 2022 and amended multiple times through 2024. This creates a new direct financial obligation per Item 2.03. The draw provides additional runway for the commercial-stage pharma company; specific use of proceeds and updated total debt load are not disclosed in the excerpt.

8-KOfficer or director changeJun 178-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Ardelyx, Inc. filed an 8-K (Items 5.02, 5.07) dated June 16, 2026, reporting both a director/officer change and shareholder vote results from its annual meeting. The excerpt is cover-page only with no vote tallies or officer names disclosed. These are routine governance disclosures; the 5.07 vote results are administrative unless contested proposals failed.

8-KPress release / Reg FDApr 308-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

ARDX reported period ending 2026-04-30 financial results (8-K Item 2.02). Investors should review the full earnings press release and any management guidance for forward outlook.

3New insider — initial holdingsApr 223
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3 (initial ownership statement) for ARDX on 2026-04-22, initiating required Section 16 reporting. Role: of Reporting Person. Beneficial ownership covers 2036 shares. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

3New insider — initial holdingsApr 33
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3 (initial ownership statement) for ARDX on 2026-04-03, initiating required Section 16 reporting. Role: of Reporting Person. Beneficial ownership covers 2036 shares. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

+ 14 other (6 13Gs · 3 proxys · 2 10-Qs · 1 routine 8-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Freestone Grove Partners LP Buys Shares of 253,692 Ardelyx, Inc. $ARDXdefenseworld.net·2d agoLevi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Ardelyx (ARDX)globenewswire.com·14d agoARDX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Ardelyx (ARDX)gurufocus.com·15d agoARDX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Ardelyx (ARDX)businesswire.com·15d agoARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyxprnewswire.com·18d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 5 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport